19.07.2019 • TopicsAxaltaPowder Coatings

Axalta to Expand German Powder Coatings Facility in Landshut

Axaltas metallic powder coatings are used in architectural and design...
Axalta's metallic powder coatings are used in architectural and design applications © Axalta

Axalta, a global supplier of liquid and powder coatings, is expanding its Landshut site in Germany, creating a second production facility in the region for bonded metallic powder coatings alongside the Montbrison plant in France.

The second production facility will enable Axalta to better respond to the increasing demand for high-quality metallic powder coatings, which are used specifically in architectural and design applications.

The new equipment will create greater efficiency and have the ability to produce small batches at short notice as needed.

Axalta’s bonded powder coatings have a high UV stability and are very durable. The coated surfaces are characterised by high brilliance, optical depth and a wide variety of amazing colour effects. These veneers are used in the coating of façade elements, profiles and aluminium and steel cladding as well as coating for windows, doors and indoor and outdoor furniture.

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.